

# Pathway for Accessing Treatments for Non-Hospitalised Adults<sup>vii</sup> with Mild COVID-19 (Effective 10<sup>th</sup> July 2023)

Supporting Information available via [GP Gateway](#)

**Patient Registered<sup>i,ii</sup> with a General Practice in Coventry and Warwickshire presents to NHS Service Provider (Trust, GP, NHS 111)**

**All NHS Service Providers Responsible for Confirming:**

1. Positive COVID-19 Lateral Flow Test
2. Symptomatic (onset within last 5 days) with COVID-19 and showing no signs of clinical recovery
3. Identified as Highest Risk (see [Independent Advisory Group Report](#))

Potentially<sup>v</sup> Eligible<sup>vi</sup>

**REFER to Respiratory@Home ASAP or within 5 days of symptom onset:**

> [GP Gateway](#)

**Notes:**

- For patients registered with a GP outside of Coventry and Warwickshire, refer to appropriate [CMDU service](#).

Not eligible

Hospital Referral if indicated

**Respiratory@Home service**

1. Check referrals daily, prioritise day 3-4 window
2. Remote triage to assess [eligibility](#) and suitability using EMIS patient note
3. Follow [NICE TA 878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19](#) to ensure appropriate treatment choice
4. Seek specialist advice where appropriate, in this case from the R@H service Clinical Lead
5. Drug interactions via [University of Liverpool COVID-19 website](#)
6. Monitor eligible and not eligible patients and provide Respiratory@Home service where needed.

**Eligible<sup>vi</sup> for COVID-19 Treatment**  
See pg 2 overleaf

**Notes:**

- I. C&W residents testing positive Out of Area (OOA) should be assessed by Respiratory@Home for Paxlovid and prescription issued to the OOA [Pharmacy \(or equivalent\)](#) service.
- II. OOA patients testing positive in C&W will need to be referred to the appropriate CMDU or equivalent within their area. Temporary registration with a C&W GP will not give access to medical notes and so triage and prescription cannot happen.
- III. Clinicians requesting LFT tests for patients potentially eligible for COVID-19 treatments should clearly annotate the request with "clinical priority group".
- IV. GP Practice teams/NHS 111 are not expected to make the final decision of whether the treatment is right for a patient or prescribe any treatment, rather to refer patients that meet the policy criteria in broad terms.
- V. The final decision about eligibility rests with the Respiratory@Home clinician.
- VI. The pathway is based on available information and clinical opinion. It will be reviewed and updated, if required, as services develop, and national policy is updated.
- VII. Please note that this is an Adult only service/pathway. For patients under 18years: please liaise directly with the relevant Paediatric team: Respiratory@Home are unable to advise on such cases.

## Eligible for COVID-19 Treatments: Treatment Choice and CMDU Responsibilities

Ensure comprehensive assessment of clinical appropriateness to guide treatment choice with reference to:  
[NICE TA 878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19](#)

Note: Please refer to the electronic versions at all times.

|                                    | 1 <sup>st</sup> line   | 2 <sup>nd</sup> line   |
|------------------------------------|--|--|
|                                    | PAXLOVID (SmPC)  | SOTROVIMAB (SmPC)  |
| <b>Clinical Check Requirements</b> | <p><b>1. <a href="#">Confirm exclusions</a> including:</b></p> <ul style="list-style-type: none"> <li>o Pregnancy</li> <li>o Severe hepatic or renal impairment<sup>1</sup></li> <li>o <a href="#">Assessing for Paxlovid treatment</a></li> <li>o <a href="#">Interactions with COVID-19 antiviral therapies</a></li> <li>o <a href="#">Liverpool Drug Interactions Checker</a></li> </ul> <p><b>2. Commence treatment within 5 days of symptom onset</b></p> <p><b>3. Counsel, specifically regarding:</b></p> <ul style="list-style-type: none"> <li>o Pregnancy and contraception</li> <li>o Gastro-intestinal side effects</li> <li>o Completion of course, missed dose</li> </ul> <p><b>4. Issue PIL (<a href="#">Paxlovid</a>); <a href="#">UKHSA leaflet</a>; <a href="#">National patient website</a></b></p>   | <p>1. Paxlovid is contra-indicated or unsuitable</p> <p>2. Confirm exclusions</p> <p>3. Use in pregnancy: where expected benefit to mother justifies the risk to the foetus; liaise with appropriate specialist</p> <p>4. Treatment is delivered within 5 days of symptom onset</p> <p>5. Counsel</p> <p>6. Issue PIL (<a href="#">Sotrovimab</a>); <a href="#">National patient website</a></p> |
|                                    | <b>1. CMDUs to contact local services for pharmacy/specialist advice as needed</b>   |  |
|                                    | <b>2. Prescribe treatment as appropriate:</b>  |  |
| <b>Advice</b>                      | <p><b>Paxlovid: Via NHS Community Pharmacies</b></p> <p><b>I. Discuss with patient:</b></p> <ul style="list-style-type: none"> <li>a. Preferred community pharmacy considering urgency of prescription.</li> <li>b. Standard prescription charges are applicable.</li> <li>c. Contacting the pharmacy to confirm when the prescription is ready.</li> <li>d. Arranging collection by an asymptomatic patient representative.</li> </ul> <p><b>II. Telephone the identified community pharmacy to:</b></p> <ul style="list-style-type: none"> <li>a. Confirm ability to fulfil prescription before sending via EPS.</li> <li>b. Confirm clinical checks have been completed.</li> <li>c. Community Pharmacists are also responsible for a clinical check and may request additional information. If requested, supply (via secure nhs.net email) the completed referral form. See page 3 for further details regarding contacting community pharmacies and arrangements for urgent supply.</li> <li>d. Advise on patient plans for medication collection.</li> </ul> <p><b>III. Complete electronic FP10 and send to selected community pharmacy:</b></p> <ul style="list-style-type: none"> <li>a. Temporary EPS nomination may be necessary, or an EPS token provided</li> <li>b. Include statement that it is a 'Covid Medicine Service Prescription' and telephone number for queries in FP10 'pharmacy info' section.</li> </ul> | <p>Sotrovimab: Via Trust Pharmacy Departments. This will be provided from the CMDUs at George Eliot Hospital and Warwick hospital.</p> <p><b>Process TBC once known</b></p>  |
|                                    | <b>3. Activity Reporting to ICB</b>  |  |
| <b>Notes</b>                       | <ul style="list-style-type: none"> <li>i. Where a decision to prescribe is reversed, please ensure that both the provider and community pharmacy, as appropriate, are notified.</li> <li>ii. Combination treatment with an nMAB and an antiviral is NOT routinely recommended</li> <li>iii. Patients who have previously received treatment with an nMAB or antiviral, &amp; who meet the eligibility criteria, may receive treatment for a subsequent episode, if clinically appropriate.</li> <li>iv. Where supply availability is impacting choice of treatment, consider MDT discussion to agree optimum treatment for the patients' circumstances.</li> </ul>   |  |

<sup>1</sup> See [SmPC](#) for dosing modification for moderate renal impairment.

## Eligible for COVID-19 Treatments: Treatment Provision & Pharmacist Responsibilities

|                                     | <b>PAXLOVID (<a href="#">SmPC</a>)</b>   | <b>SOTROVIMAB (<a href="#">SmPC</a>)</b>               |
|-------------------------------------|--|--|
| <b>Responsibilities and Actions</b> | Via selected Community Pharmacies: <ul style="list-style-type: none"> <li>These pharmacies are requested to keep 2 packs of Paxlovid in stock.</li> <li>Respiratory@Home have been supplied with direct contact details of pharmacies.</li> </ul>  | Via Trust Pharmacy departments: Details TBC when known |
| <b>Treatment provision</b>          | <ol style="list-style-type: none"> <li>1. Draw down prescription from the spine.</li> <li>2. Confirm:                             <ol style="list-style-type: none"> <li>a. prescription has been generated by the triaging clinician</li> <li>b. clinical check has been completed by prescriber</li> <li>c. there are no outstanding concerns to preclude use of Paxlovid</li> </ol> </li> <li>3. Pharmacy Clinical Check and Dispensing Pharmacists are responsible for a clinical check. Additional clinical information including the completed Checklist may be requested from the prescriber, who will supply via secure nhs.net email.</li> <li>4. Provision of <a href="#">Paxlovid Patient Information Leaflet (PIL)</a>, additional UKHSA <a href="#">Paxlovid</a> leaflet and a pulse oximeter and further patient information (if the patient agrees with the triaging clinician to be monitored by the Respiratory@Home team). (Community pharmacies can have oximeters supplied by Respiratory@Home team).</li> <li>5. Counsel patient in line with Paxlovid PIL, specifically regarding:                             <ol style="list-style-type: none"> <li>i. Pregnancy and contraception</li> <li>ii. Gastro-intestinal side effects</li> <li>iii. Completion of course, and missed dose</li> </ol> </li> <li>6. Collect standard prescription charge if applicable</li> </ol> | Further details to be added once confirmed             |

### Resource Signposting

1. In addition to resources on pages 1 and 2 of this document, a complete list of resources are available via [Liverpool COVID-19 Interactions \(covid19-druginteractions.org\)](https://www.liverpooldruginteractions.org/) including:
 

|  |  |
|--|--|
| <ul style="list-style-type: none"> <li><a href="#">Guidance for resuming paused or dose-adjusted comedications with Paxlovid</a></li> <li><a href="#">Swallowing Difficulties - Administering Paxlovid as Crushed Tablets</a></li> <li><a href="#">Guidance for Paxlovid dosing in patients with renal disease and patients on dialysis</a></li> </ul> | <ul style="list-style-type: none"> <li><a href="#">COVID-19 Therapies – Dose Recommendations for Patients with Renal Impairment</a></li> <li><a href="#">COVID-19 Therapies - Dose Recommendations for Patients with Hepatic Impairment</a></li> </ul> |
|--|--|
2. [COVID-19 Antivirals – Community Pharmacy Coventry and Warwickshire](#)
3. Specialist Pharmacy Service Medicines Advice contact details: telephone 0300 770 8564 or email: [asksps.nhs@sps.direct](mailto:asksps.nhs@sps.direct)
4. E-Learning training materials: COVID-19 Treatments is available [here](#) (Registration on NHS Learning Hub is required)
5. [PAXLOVID ▼ \(nirmatrelvir/ritonavir\) - PfizerPro UK](#)
6. [Key Opinion Leader videos](#) including: managing drug-drug interactions, importance of managing COVID, identifying & educating high risk patients
7. [Specialist Pharmacy Service: Accessing COVID-19 Medicines Advice for Primary Care](#)